Mucolipin-1 (TRPML1) (TRPML1)

Mucolipin-1 (TRPML1) is a non-selective cation channel primarily localized to the membranes of late endosomes and lysosomes, where it facilitates the efflux of calcium into the cytosol (UniProt: Q9GZU1). This channel is a critical regulator of lysosomal dynamics, influencing processes such as organelle fusion, fission, and the transport of macromolecules (PubMed: 20005808). Mutations in the MCOLN1 gene lead to Mucolipidosis type IV, a lysosomal storage disorder characterized by severe neurological and ophthalmological deficits (NIH: GARD). Beyond rare genetic diseases, TRPML1 is a major focus in neurodegeneration research because its activation can stimulate the clearance of toxic protein aggregates like amyloid-beta and alpha-synuclein (PubMed: 26455740). Therapeutic strategies often involve small-molecule agonists designed to enhance lysosomal proteolysis and autophagy. Conversely, in certain cancers, TRPML1 is upregulated to support the high metabolic demands of tumor cells, making its inhibition a potential strategy for oncology (PubMed: 31006537). The development of TRPML1-targeted therapies requires careful consideration of channel specificity to avoid off-target effects on other transient receptor potential family members.

Other names

MCOLN1ML1MLIVTRP-ML1Transient receptor potential mucolipin 1Mucolipin 1

Agonism of the TRPML1 channel to trigger lysosomal calcium release and activate TFEB-mediated lysosomal biogenesis, thereby enhancing autophagic clearance of cellular debris; inhibition to disrupt lysosomal function in cancer cells (PubMed: 26455740, PubMed: 31006537).